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Introduction
Parathyroid hormone (PTH) is the major calcium-regulating hormone in humans. In
addition to its actions on calcium metabolism, decades of animal and human studies
have shown that PTH can be a potent anabolic agent when administered
intermittently. Currently, it has been Food and Drug Administration approved for the
management of post-menopausal and idiopathic osteoporosis. In bone, PTH binds to
PTH1R receptors on osteoblasts, initiating three molecular cascades: an increase in
intracellular calcium, and the activation of the protein kinase C (PKC) and protein
kinase A (PKA) pathways. The anabolic effect of PTH on bone mass acquisition is
mediated by the PKA signaling pathway. However, the exact molecular mechanisms
of PTH signaling are complex and still not fully understood.

Our laboratory examines the role ofthe cAMP responsive element modulator (Crem)
gene, a member of the basic leucine zipper (bZIP) ATF/CREB family of transcription
factors, in the PTH anabolic response. The Crem gene encodes the inducible cAMP
early repressor (lCER), which acts as a dominant regulator of gene transcription
because it contains essentially only the DNA binding domain ofCREM [1]. Previous
studies demonstrated that PTH rapidly and transiently induces ICER in osteoblastic
cells via the PKA pathway [2, 3].

To better understand the role of lCER, Huang et al developed transgenic mice with
osteoblast-targeted expression ofICER[4]. These transgenic mice have low bone
mass, impaired osteoblast differentiation and increased osteoclast precursors in bone

marrow. This mouse model suggests that the ICER transgene disrupts the activity of
ATF/CREB factors required for normal bone remodeling [4]. Further study is needed

to determine the in vivo specificity of ICER protein, including if in the presence of an
induced anabolic stimuli ICER has the sole ability to disrupt bone mass acquisition.

Parathyroid hormone

Parathyroid hormone (PTH) is secreted by the parathyroid glands in response to
changes in serum calcium (4). More specifically, there are calcium receptors on the
parathyroid glands which regulate the feedback loop between PTH and serum
calcium levels. It is PTH which acts to balance both bone resorption and bone
formation. PTH binds to PTHRI receptors on the surface of osteoblasts and engages
three signaling pathways: PKA, PKC and intracellular calcium (Figure 1).

The PKA pathway involves the formation of cAMP, the binding of cAMP to the
regulatory subunit ofPKA, which then releases the active catalytic subunits [5].
These subunits then translocate to the nucleus and phosphorylate the transcription
factor CREB (cAMP response element binding protein), leading to the expression of
cAMP-inducible genes [6].

The unique anabolic ability of PTH to stimulate activation of remodeling units, which
enhance bone formation over resorption, has led to the growing interest in the
therapeutic efficacy ofPTH [7]. Currently, parathyroid hormone (PTH) is approved
for the management of post menopausal and idiopathic osteoporosis. Decades of
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animal and human studies of PTH have discovered that variables such as dosing
regimens, duration of treatment and dose magnitude determine if the effects will be
anabolic or catabolic[8]. However, the exact mechanisms ofPTH's action are
complex and not yet fully understood. A clearer understanding of the molecular
mechanisms responsible for the anabolic action of PTH on both cortical and
trabecular bone will aid in designing better treatment options.

PTH has been shown to be an effective anabolic agent in humans, rats, rabbits and
primates when administered intermittently [7-9]. Clinical studies in humans have
found the anabolic effects of PTH to be both time and dose dependent. The use of
PTH(1-34) or PTH(1-84) results in a peak semm concentration of approximately 60
to 120 minutes and a disappearance at 6 to 8 hours [7]. At least three randomized
clinical studies found that from daily PTH injections there is a significant increase in
bone mineral density at trabecular bone sites, that bone remodeling is enhanced with
markers of bone formation rising early followed by an increase in bone resorption,
and that bone strength increases by way of greater trabecular, cortical and overall
bone volume[7]. In these trials, daily subcutaneous injections ofPTH increased spinal
bone mass density by only 8-10%. Bone mineral density increases in the femur and
total body were considerably less ranging from 3-5% and radial bone mineral density
either declined slightly or remained the same when measured by dual X-ray energy
absorptometry [7]. The more significant finding was a time-dependent marked
fracture risk reduction even in sites that showed no increases in bone mineral density
[7]. Also, suggesting a change in the quality of bone.
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The most common animal model used has been the ovariectomized animal, which
closely resembles the skeletal loss due to estrogen deprivation seen in
postmenopausal humans. In this model, it was discovered that intermittent PTH
prevented the 50% trabecular bone volume loss post ovariectomy and increased bone
formation by increasing bone apposition on the periosteal and endosteal surfaces,
while intracortical bone was renewed through remodeling [7, 8]. More studies have
examined the skeletal effects of PTH therapy but only a few studies have looked at
the effects in oral osseous tissue in the aged ovariectomized rat model. After an
intermittent PTH protocol (5 days a week for 10 weeks), Miller et al found no effect
on dentin formation from the incisors but most indices of bone formation, including
the double-labeled surface, mineralizing surface, mineral appositional rate, new bone
area and surface-referent bone formation rates, were greater in the PTH-treated group
compared with both the Ovx and the Sham controls measured at the periosteal and
cancellous bone surfaces of the mandible [10].

More recently, the mouse model has been used to study the anabolic effects of PTH at
the molecular level. An advantage of using this model is the ability to genetically
alter the mouse and study the effects of anabolic agents at the molecular level. In
2002, Iida-Klein et aI, studied how bone mineral density changes with age in the
murine skeleton of C57BLl6J mice, when peak bone mass is achieved and whether
there are any site-specific effects of intermittent PTH treatment [11]. They found that
with daily PTH injections, there was an increase of gene expression in bone formation
and resorption in the post-adolescent female mouse and that bone mineral density
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increased at all sites including the tibia, femur, and total body. These results are
similar to the above actions ofPTH observed in humans and rats and, thus,
demonstrate that it is a viable model in which to study the anabolic effects ofPTH.

Inducible cAMP Early Repressor
The cAMP responsive element modulator (CREM) gene, is a member of the
CREB/ATF family of basic leucine zipper transcription factors [2]. This gene gives

rise to multiple proteins by alternative splicing of the CREM transcript and using
alternative promoters [3]. These proteins function as transcriptional activators or
repressors by binding to cAMP response elements (CREs). In 1993, Molina et aI,
identified and characterized one such protein called the inducible cAMP early
repressor (ICER)[l].

ICER transcripts are transcribed from the intronic promoter P2 of the CREM gene.
By alternative splicing, four isofornls are transcribed: I, I galllffia, II, and II gamma
[1,3] (Figure 2). ICER proteins contain a unique N-terminal amino acid sequence
and either DNA binding domains (DBD) I or II but lack the kinase-inducible domains
of CREM. Thus, ICER proteins in most cases act as transcriptional repressors [3].

The functions ofICER are two-fold: to inhibit transcription of cAMP-induced
transcription by binding to promoter sequences or by fornling inactive heterodimers
with other bZip transcription factors [1]; ICER also has the unique ability to regulate
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its own transcription by binding to the CARE site, two pairs of clustered cAMP
response elements, in the P2 promoter of the CREM gene (Figure 3).

While PTH is known to induce multiple gene expression in osteoblasts, Tetradis et al
specifically, examined whether PTH induced the ICER protein. They showed that
PTH did induce all known ICER transcripts in MC3T3-El cells and neonatal mouse
calvariae with mRNA levels peaking at 2 to 4 hours and declining to baseline by 10
hours [3]. Thus, ICER's expression is characterized as rapid and transient.

In a later study, the pathways through which PTH induces ICER; these could be PKC,
PKA and/or calcium influx) [2]. Their results revealed that only agents that signal
through the cAMP-PKA pathway were able to induce ICER and positive and negative
manipulation of this pathway significantly effected ICER expression.

Transgenic Mouse Model

In an effort to study to the functions of ICER in vivo, Huang et al developed a
transgenic mouse with osteoblast-targeted expression ofICER [4]. The pOBCo13.6ICER I and II transgenes were constructed by cloning ICER I and ICER II cDNAs,
each containing an N-terminal FLAG epitope tag, downstream of a fragment
containing a 3.6-kb fragment of the rat Collal promoter and most of the rat Collal
first intron. Four lines of transgenic mice in the CD-l background were generated by
embryo microinjection.

6

Of all the lCER I transgenic lines tested, line 284 has the highest trans gene mRNA
expression in bone [4]. This line has lower body weight and decreased bone mineral
density (determined by DEXA) than wild-type littermates. Serum osteocalcin, a
marker of bone formation, was reduced in the serum of transgenic mice. Furthermore,
histological sections of distal femurs showed almost no trabecular bone, and
histomorphometry showed a significant reduction in percent trabecular bone volume.
Dynamic histomorphometry revealed a significant decrease in the mineral apposition
rate (MAR) and bone formation rate per bone surface (BFRlBS).

Microcomputed tomography (microCT) was done to assess bone morphometry. Three
dimensional images of femoral sections revealed a dramatic reduction in the
trabecular bone compartment. Accordingly, morphometic analysis showed a
reduction in trabecular bone volume, number and thickness. Cross-sectional images
through the mid-diaphaseal region of femurs showed a significant decrease in cortical
bone area and thickness. Additionally, in a subsequent unpublished study performed
in our laboratory, microCT of the lCER transgenic mandibles revealed a mark
reduction in bone volume with respect to total bone volume, generalized pitting of
bone and a statistically significant reduction in cortical tissue density [12].

To examine the effect of the lCER transgene on osteoblast differentiation, a green
fluorescent protein (GFP) trans gene (pOBCoI2.3-GFP) was bred into the lCER mice
as a marker of late osteoblast differentiation [4]. They showed that bone marrow
cultures from lCER mice had impaired osteoblast differentiation. Although osteoclast
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number per bone surface was not significantly altered in femoral trabecular bone from
ICER mice, osteoclast precursors were increased 2-fold in the transgenic bone
marrow cultures. Thus, these collective results indicate that the low bone mass in
transgenic mice with osteoblast-targeted ICER expression was caused by a
dysregulation of both bone formation and resorption. This transgenic model suggests
that ICER disrupts molecular pathways that are critical for normal bone remodeling.

Significance and Rationale of Research
PTH (1-34) is currently FDA approved and being effectively used in osteoporosis [7].
While antiresorptive agents are used to increase the mineral content of existing bone,
they cannot cause an increase in bone mass [9]. However, when administered
intermittently PTH can build both cortical and trabecular bone [8]. The treatment
protocol requires single daily injections and is not without disadvantages such as cost,
compliance and even potential risk of malignant transformation [7]. Despite its use,
the exact mechanisms responsible for the anabolic actions of PTH are still not fully
understood. Identification of these molecular mechanisms, will aid in the design of
better treatment options, not just for the treatment of post-menopausal osteoporosis
but for other metabolic bone diseases.

Our current understanding ofthe molecular mechanisms on osteoblast cell is that the
binding ofPTH to osteoblasts induces three molecular cascades: extracellular calcium
influx, activation of the PKC pathway and activation of the PKA pathway [5].
Induction of the PKA pathway leads to induction of cAMP inducible genes.
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Furthermore, previous studies have found that the cAMP signaling pathway induces
ICER expression in many cell types which then represses cAMP-induced
transcription of other genes including its own transcription [1].

In 1998, Tetradis et al studied the effects ofPTH on osteoblastic MC3T3-EI cells and
mouse calvarie and found that it rapidly and transiently induced ICER mRNA[3]. A
subsequent study, found that only manipulation of the cAMP-PKA signaling pathway
affected the expression ofICER mRNA and protein [2]. In addition, the osteopenia in
the transgenic mice with osteoblast-targeted overexpression of ICER suggests that
ICER disrupts the molecular pathways that govern normal bone remodeling [4].
Therefore, we believe in vivo that PTH-induced ICER is a physiological regulator of
downstream target genes. In ICER transgenic mice, thus, the response of bone to PTH
should be blocked.

Objective of Research

The goal of this research was to determine whether ICER transgenic mice have an
altered response to an intermittent PTH treatment protocol. Previous studies have
shown that PTH and cAMP induce ICER gene expression in osteoblasts and that the
anabolic effect ofPTH is mediated by the cAMP-PKA pathway [2]. Our objective
was to determine if ICER overexpression will prevent the acquisition of bone mass by
intermittent PTH treatment.
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Specific Aim
The aim of this study was to examine bone density, morphology and cellular response
of ICER transgenic mice to an intermittent PTH injection protocol. This involved
injection of wild type and ICER transgenic mice 5 times per week for four weeks
with 80 J.1g/kg of PTH. Bone mass, bone micro-architecture and osteoblast activity
were then measured by DEXA, micro CT, serum osteocalcin levels and dynamic
histomorphometry .

Hypothesis
An anabolic PTH treatment protocol in ICER transgenic mice does not increase bone
mass.
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Materials and Methods
Mice
The cohorts of mice used consisted of 20 female, 10- to l1-week-old CD-l wild-type
mice and 17 female, 10- to 11-week-old line 284 ICER transgenic mice. The groups
were derived from four different breeding units (Figure 4). All mice were divided
into four treatment groups: wild-type PTH-treated, wild-type vehicle-treated, ICER
transgenic PTH-treated, and ICER transgenic vehicle-treated. All animal protocols
were approved by the institutional Animal Care and Use Committee (protocol #2006215).

Pre-experimental Measurements

Weight
Total body weights of all mice were recorded using a digital scale.

Anesthesia
Mice were anesthetized using a precision vaporizer that supplied isof1urane at a
desired concentration in pure oxygen flow (1.5-2% isoflurane with 250 mllmin O 2).

Bone Mineral Density
To determine baseline whole body bone mineral density, each mouse (under
anesthesia) was subjected to a PIXlmus Dual Energy X-ray Absorptiometry (DEXA)
densitometer (Lunar Corporation, Madison, WI). The machine was initially calibrated
with a phantom of a defined value.
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Preparation of PTH and Vehicle Solutions
Human PTH(1-34) (Bachem Bioscience Inc, King of Prussia, PA, USA) was
dissolved in 1 mg/ml BSAlO.Ol N Hel (vehicle) to prepare a dosing solution. Mice
were injected with vehicle or PTH. Mice received a final dosage of 80 IJ-g/kg of PTH.
The concentration of the dosing solution was determined from the average weight of
the wild-type mice and transgenic mice.

Injection Protocol
Human PTH(1-34) solution and vehicle solution was injected once daily for 5
consecutive days, then 2 days off, for 4 weeks. Subcutaneous injections between the
scapulas were done with a small 27-gauge needle using a 0.5 ml insulin syringe. The
injection volume for wild type mice was 0.050 ml while the injection volume for
transgenic mice was reduced by the percentage average body weight difference
compared to wild-type mice (usually about 30%). As mentioned above, all mice
received the same dose of PTH based on body weight.

Markers for Bone Labeling
Ten days prior to sacrifice, all mice were injected with calcein intraperitoneally
(Sigma, St. Louis, MO) at 10 mg/kg body weight with a small 27-gauge needle using
a 0.5 ml insulin syringe. Then, two days prior to sacrifice, mice were injected
intraperitoneally with xylenol orange (Sigma, St. Louis, MO) at 90 mg/kg body
weight.
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Experimental Endpoint Measurements

Weight
At 14-15 weeks (end of the experiment), total body weight was recorded on a digital
scale. Mice were sacrificed by CO2 asphyxiation followed by cervical dislocation.

Serum Bone Turnover Markers
Blood was obtained by cardiac puncture. Samples were allowed to clot for at least 30
minutes and then centrifuged for 10 minutes at 1,000 x g. Serum was removed
immediately and stored at -20 degrees C. Serum osteocalcin was measured by
radioimmunoassay using a goat anti-mouse osteocalcin antibody [13] by Dr. Caren
Gundberg ofthe Yale University Core Center for Musculoskeletal Disorders. The Cterminal telopeptide of ul(I) collagen was measured by an enzyme-linked
immunosorbent assay (ELISA) using a RatLaps kit (Nordic Bioscience Diagnostics,
AlS).

Bone Mineral Density
Mice underwent full body DEXA to determine post-experimental whole body bone
mineral density. The machine was initially calibrated with a phantom of a defined
value.

MicroCT
Dissected femurs, L3 vertebrae and hemi-mandibles (bisected at the symphysis) were
fixed in 70% ethanol and analyzed by MicroCT. Trabecular morphometry within the
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metaphyseal region of distal femurs and the centrum of the third lumbar vertebrae
was quantified using microCT (/lCT40, Scanco Medical AG, Bassersdorf,
Switzerland). Three-dimensional images were reconstructed using standard
convolution back-projection algorithms with Shepp and Logan filtering, and rendered
within a 12.3 mm field of view at a discrete density of 578,704 voxels/mm3 (isometric
12-/lm voxels). Segmentation of bone from marrow and soft tissue was performed in

conjunction with a constrained Gaussian filter to reduce noise. For volumetric
analysis, regions were selected within the endosteal borders to include the central
80% of vertebral height and secondary spongiosa of femoral metaphyses located 960
/lm

(~6%

of length) from the growth plate. Trabecular morphometry was

characterized by measuring bone volume fraction (BV/TV, %), connectivity density,
surface density (BS/TV), trabecular thickness (TbTh), trabecular number (TbN), and
trabecular spacing (TbSp).

Cortical morphometry was also evaluated in femurs using microCT. Threedimensional images were reconstructed using standard convolution backprojection
algorithms with Shepp and Logan filtering, and rendered at a discrete density of
578,704 voxels/mm3 (isometric 12 /lm voxels). Bone was threshold segmented from
marrow and soft tissue at an attenuation coefficient of2.8 cm- I . Cortical
morphometry was quantified and averaged for fifty cross sections (600 /lm) at the
mid-diaphysis, measured between proximal and distal growth plates. Direct
measurements of cross-sectional geometry provided subperiosteal area, subendosteal
area, and cortical areas. A circular model was applied to the periosteal and
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subendoesteal area magnitudes to calculate average values of the cortical width,
periosteal and endosteal radii, and periosteal and endosteal perimeters.

A qualitative and quantitative 3-dimensional analysis of hemi-mandibles was
performed using microCT. The hemi-mandibles were scanned in cross section from
the incisal edge of the incisor to the condyle of the mandible and 12 micron sections
were acquired. Analysis was performed at three different locations along the length
of the mandible: 1) the alveolar crest, the first section in which the alveolar bone is
seen; 2) the level of the first molar at the center of the mesial root; and 3) the level of
the third molar, first section in which the second molar cannot be seen. The
measurements included bone volume (BVlTV) and tissue density of enamel, labial
dentin and lingual dentin of the incisor at all 3 sites mentioned above.

Histomorphometry
Histomorphometry was done to evaluate rates of bone formation and mineralization.
L3 vertebrae were put into 70% ethanol, then fixed, dehydrated, cleared, embedded in
plastic, and sectioned. The sections were then deplasticized and evaluated by
fluorescence microscopy. The measurements were taken at approximately 200
microns from the epiphyseal growth plate. All dynamic parameters were measured
according to the Report of the ASBMR Histomorphometry Nomenclature Committee
[14].
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Statistical Analysis
In the figures, all values shown are the mean ± SD of the number of values indicated.
Data between groups was analyzed with unpaired student's t-tests. A p'value of <0.05
was considered significant.
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Results
Percent Change in Body Weight
Weight was recorded in grams before and after the treatment protocols and the
percent change was recorded. The percent change in body weight between the wildtype PTH treated group (l4.6±4.8) and the wild-type vehicle treated group (8.2±7.6)
was significant. In contrast, the percent increase in body weight was not significant
between the ICER transgenic PTH group (13.7±9.4) and the ICER transgenic vehicle
group (12.S±17.3) (Figure 5).

Bone Mineral Density and Bone Mineral Content
F or each group, the percent change in bone mineral density and bone mineral content

was analyzed. The wild-type PTH group showed an increasing trend (p=.06) in bone
mineral density when compared with the wild-type vehicle group (Figure 6).
However, the transgenic PTH group did not demonstrate a significant change in bone
mineral density compared to the transgenic vehicle group (Figure 7). Neither the
wild-type nor the transgenic groups had a significant change in bone mineral content.

Serum Osteocalcin
Serum osteocalcin levels were measured after the treatment protocols. There was a
significant increase in serum osteocalcin (p=.03) in the wild-type PTH treated group
compared to the wild-type vehicle treated group (Figure 8). However, serum
osteocalcin levels in the transgenic group did not increase after treatment with PTH
(Figure 9).
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Microcomputed Tomography

Femur
The cortical bone of the femurs was the most responsive to PTH treatment. The wlldtype group showed a significant change in cortical thickness measured in mm after
PTH therapy (Figure 10). The transgenic group had an increasing trend (p=.06) in
cortical thickness. Interestingly, the TG group did show a significant increase in
cortical porosity after PTH treatment which was not seen in the wild-type group
(Figure 11). Therefore, an examination of the segmented cortical bone area measured
in mm2 was performed to evaluate the cortical bone without the voids. There was a
small increasing trend (p=.l) in cortical bone area in the wild-type group after the
PTH treatment, and a significant increase in cortical bone area in the transgenic group
after PTH treatment (Figure 12).

The trabecular bone of the femurs was not very responsive to PTH in our study. No
significant changes in trabecular bone volume fraction (BVlTV) were seen in the
wild-type or transgenic groups after PTH treatment. However, within the wild-type
group, there was a significant increase in trabecular thickness (Figure 13). Changes
in mean trabecular number and spacing were not significant in either the wild-type or
transgenic groups.

Vertebrae
The trabecular bone of the L3 vertebrae had some varied and unexpected responses to
PTH treatment. The wild-type group did not respond to the PTH with a significant
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increase in trabecular BV/TV. However, there was a significant increase in trabecular
BV/TV in the transgenic group after the PTH treatment (Figure 14).

Mandible
The 3-dimensional reconstructions of the mandibles showed an obvious bone
phenotype in the transgenic mice. The transgenic mandibles showed generalized
pitting of the bone and severe loss of alveolar bone around the molars (Figure 15).
Interestingly, a common finding noted within the transgenic group was the loss of
molars. It is unclear if they were lost in the mice in vivo or whether they fell out
during dissection and/or analysis. There were, however, no apparent PTH effects on
the bone phenotype within the wild-type or transgenic groups.

Cross-sectional, quantitative analyses of cortical bone were performed at the mesial
roots ofthe first and third molars. After PTH treatment, neither the wild-type nor
transgenic groups showed a significant increase in BV/TV (Figure 16). There was a
significant decrease in cortical bone at the 1st molar and 3rd molar regions noted in the
transgenic group compared to the wild-type group typical ofthe ICER transgenic
bone phenotype.

Histomorphometry
The dynamic labeling of sectioned L3 vertebrae was evaluated and measured to
confirm and extend the microCT analyses. The wild-type group showed a trend
(p=.07) toward increased mineral apposition rate (MAR) after the PTH treatment;
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however, there was no change in the bone formation rate per bone surface (BFRlBS)
(Figures 17 and 18). In contrast, the transgenic group showed a trend (p=.06) toward
increased BFRIBS but not a change in the mineral apposition rate (MAR) (Figures 19
and 20).
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Discussion
Previous studies have examined the expression of ICER in osteoblasts in vivo and in
vitro. Molina et al demonstrated the repressive functions ofICER[I]. Tetradis et al
showed that ICER is induced by PTH and cAMP in osteoblastic cells[3]. Later,
Nervina, et al showed that the expression ofICER in osteoblasts is coupled to the
cAMP-PKA signaling pathway[2]. These findings have led to the hypothesis that
ICER induction in osteoblasts acts as a mechanism to regulate cAMP-dependent gene
expression, and that it could affect the magnitude or time course of gene expression in
response to hormones, such as PTH, that stimulate cAMP production.

To evaluate the in vivo role of ICER in bone, our laboratory has used two mouse
models: CREM-knockout mice and transgenic mice with osteoblast-targeted
expression ofICER. Lui et al studied the effects ofPTH administration in CREMknockout mice[15]. He showed that CREM deficiency alters the response of bone to
PTH such that osteoclastogenesis is increased. This blunts bone mass acquisition in
response to PTH treatment. Furthermore, our laboratory developed and characterized
a transgenic mouse model with an overexpression ofICER in cells of the osteoblast
lineage (pOBCo13.6-ICER) [4]. The osteopenic phenotype suggests that ICER may
disrupt bone remodeling.

The present study was designed to examine the response of ICER transgenic bone to
an anabolic dosage of PTH. Initial tests to evaluate bone formation did not reveal
significant increases in bone mineral density or serum osteocalcin levels. After
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evaluating specific bones, we did see increases in bone mass after measuring the
femoral cortical bone area and the vertebral trabecular bone volume in the transgenic
mouse after PTH treatment. The wild-type responded with a significant increase in
femoral cortical thickness, but the wild-type vertebral trabecular bone did not respond
to PTH treatment. Our results indicate that there are site specific anabolic responses
to PTH in ICER transgenic mice, suggesting that even in the presence of increased
ICER protein, there are still selected responses to PTH.

The changes in femoral cortical bone versus trabecular bone found in the wild-type
mouse after PTH treatment are consistent with what Wang et aI, found in CD-l mice
[16]. Given that the population ofthis study included only female mice, it is
interesting to note that Wang et al also reported that the anabolic response was
blunted in female CD-l mice versus male CD-l mice. In our study, the significant
increase in cortical bone volume and increasing trend in cortical bone area in the
wild-type was also reflected in the increasing trend in bone mineral density
determined by DEXA and the significant increase in serum osteocalcin levels.

The PTH treatment protocol appeared to induce significant porosity in the femoral
cortical bone of the transgenic mice. A response not noted in the wild-type. This is
probably indicative of increased osteoclast activity but, of course, it is in need of
further study. Regardless, we still noted a trend toward increased femoral cortical
thickness and a significant increase in cortical bone area within the transgenic mice.
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The fact that the lumbar vertebrae in the wild-type mice did not respond with an
increase in bone volume as seen in previous studies using the C57BLl6 black mouse
may be due to the mouse strain differences or to the PTH protocol being limited to
only 4 weeks [11]. CD-I, an outbred strain, and the C57BLl6, an inbred strain, may
have different skeletal site specific responses or dose responses to PTH treatment; this
warrants further study. In addition, Iida-Klein et al found C57BLl6 mouse vertebrae
had less of an anabolic response than the long bones; moreover, the anabolic effects
of PTH on vertebrae were only significant after 7 weeks of treatment [ 11]. However,
after only a 4 week treatment period, we did find a trend toward increased mineral
apposition rate (MAR) of the wild-type lumbar vertebrae. This may indicate enhanced
osteoblastic activity at the cellular level, but a longer treatment protocol would be
needed to study this response further.

The bone phenotype ofICER transgenic mice needs to be considered when analyzing
the results. First, this mouse model has almost no trabecular bone in the femur and
reduced template in the vertebrae. Second, long term changes in body weight and
bone mineral density have yet to be characterized. Third, we noted that the population
of ICER transgenic mice varies greatly in terms of body weight percent changes and
physical deformities even at the same age. The average percent change in body
weight of the transgenic mice was 12 percent but some of the mice had extreme
changes such as an increase in body weight by 49 percent or a decrease in body
weight by 5.5 percent. Some of the transgenic mice suffered from Kyphosis and/or
malpositioned rear feet.
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In our study, the transgenic mice did not respond to PTH with a significant increase in
full body bone mineral density or serum osteocalcin. Yet, the bone volume fraction
(BVlTV) of the lumbar vertebrae was significantly increased. Furthem1ore, the
increased trend in the bone formation rate per bone surface (BFRJBS) of the vertebrae
is indicative of a greater number of osteoblasts producing bone, and thus of an
increase in bone formation at the tissue level. These findings suggest either skeletal
site or dosage specificity within ICER transgenic mice, or that the baseline amount of
vertebral bone was sufficient to show an increase. Where as, the femoral trabecular
bone template may have been too limited to demonstrate such an increase.

The fact that the PTH protocol did not have a significant effect on mandibular bone of
the wild-type or the transgenic groups may be due, again, to treatment time, dosage or
site-specificity within the murine breed. However, Miller, et al showed significant
PTH effects in the mandible; the treatment protocol of 80 micrograms per kilogram of
body weight lasted longer, 10 weeks versus 4 weeks, and was given to
ovariectomized rats. A literature search does not reveal any published studies on the
effects of PTH on the mandibular bone in CD-l mice.
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Conclusion

We hypothesized that ICER would block bone mass acquisition in the presence of an
anabolic treatment protocol of PTH, but our experiment suggests that ICER
transgenic mice maintain selected responses to PTH. Further, the fact that ICER
transgenic mice responded with an anabolic response in the trabecular bone of the
vertebrae which was not seen in the wild-type mice demonstrates a site-specific PTH
response in this particular mouse model. However, it is still unclear the exact
magnitude oflCER's effects on cAMP induced gene expression by PTH. Perhaps,
PTH anabolic gene expression occurs by a molecular pathway other than the PKA
pathway, or that other CREM/CREB/ATF family products are involved in the
anabolic response to PTH.

To better understand ICER's effects in the presence ofPTH in the ICER transgenic
mice, future study is needed. First, a study is needed to compare the responses of
C57BLl6 and CD-l mice to PTH including various skeletal sites, dosages and time
courses. Second, analysis of the osteoclast activity is needed to evaluate the trend in
increased femoral cortical porosity after PTH treatment in the ICER transgenic mice.
Third, due to the variable changes in body weight and findings of skeletal deformities
seen amongst the ICER transgenic population, pre-treatment in vivo microCT would
allow us to observe skeletal changes over time in individual mice.
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In the future, we will need to generate and evaluate an ICER specific knockout
mouse. Collectively, data from the three mouse models should allow us to better
characterize ICER's role in bone.
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Figure Legend
Figure 1: Osteoblastic cell signaling mediated by PTH. Figure 1 is from
Swarthout, J.T., et aI., Parathyroid hormone-dependent signaling pathways

regulating genes in bone cells. Gene, 2002. 282(1-2): p. 3. PTH binds to PTHR1
receptors on the surface of osteoblasts and engages three signaling pathways: PKA,
PKC and intracellular calcium.

Figure 2: Diagram of the Crem gene and ICER isoforms. The ICER protein is
transcribed at the P2 promoter of the Crem gene. Four ICER isoforms (1, I gamma, II,
II gamma)are produced from the alternative splicing of either or both the gamma
domain and DNA binding domain 1. The Diagram was kindly provided by Taranpreet
Chandhoke.

Figure 3: The role of ICER in the regulation of gene expression by cAMP. Figure
9 is from Molina, C.A., et aI., Inducibility and negative autoregulation of CREM: an

alternative promoter directs the expression of ICER, an early response repressor.
Cell, 1993.75(5): p. 886. The schematic demonstrates that the function oflCER via
the PKA pathway is two-fold. ICER inhibits transcription of cAMP-induced genes by
binding to cAMP response elements (CREs). It also has the unique ability to regulate
its own transcription by binding to CARE sites, two pairs of clustered cAMP response
elements, in the P2 promoter of the Crem gene.
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Figure 4: Number of mice and breeding units. The table shows the study

population and the breeding units from all 4 experiments: 10 wild-type PTH treated
mice, 10 wild-type vehicle treated mice, 10 transgenic PTH treated mice and 7
transgenic vehicle treated mice.

Figure 5: Percent change in body weight. The graph demonstrates that the percent

change in body weight between the wild-type PTH treated group (14.6±4.8) and the
wild-type vehicle treated group (8.2± 7.6) was significant. In contrast, the percent
increase in body weight was not significant between the ICER transgenic PTH group
(l3.7±9.4) and the ICER transgenic vehicle group (l2.5±17.3).

Figure 6: Wild-type percent change in bone mineral density. The graph

demonstrates an increasing trend (p=.06) in percent change in full body bone mineral
density between the wild-type vehicle group (n=7, 1.45±2.92) and the wild-type PTH
group (n=6, 5.31±3.55).

Figure 7: Transgenic percent change in bone mineral density. The graph

demonstrates no percent change in full body bone mineral density between the
transgenic vehicle group (n=6, mean 4.35±4.48) and the transgenic PTH group (n=5,
2.83±3.72).
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Figure 8: Wild-type serum osteocalcin levels. The graph demonstrates a significant
(p=.03) increase in serum osteocalcin levels between the wild-type vehicle group
(n=6, SO.83±IO.68) and the wild-type PTH group (n=6, 62.83±14.4).

Figure 9: Transgenic serum osteocalcin levels. The graph demonstrates no change
in serum osteocalcin levels between the transgenic vehicle group (n=6, 3S.S±6.98) ant
the transgenic PTH group (n=S, 38.8±IO.78).

Figure 10: Microcomputed tomography analysis of femoral cortical thickness.
Microcomputed tomography through the mid-diaphysis of the femur showed a
significant increase in cortical thickness measured in millimeters between the wildtype vehicle group (n=IO, 0.2S6±O.OI) and the wild-type PTH group (n=lO,
O.274±O.OI). There was an increasing trend (p=.06) in cortical thickness noted
between the transgenic vehicle group (n=6, O.19S±O.003) and the transgenic PTH
group (n=IO, O.230±O.03).

Figure 11: Microcomputed tomography analysis of cortical porosity.
Microcomputed tomography through the mid-diaphysis ofthe femur showed a
significant (p=.OS) increase in porosity (%) of the cortical bone between the
transgenic vehicle group (n=6, 3.4±2.8) and the transgenic PTH group (n=lO,
6.7±2.9). Cortical porosity did not change between the wild-type vehicle group
(n=IO, 1.6±1.1) and the wild-type PTH group (n=IO, mean 2.4±1.1).
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Figure 12: Microcomputed tomography analysis of femoral cortical bone area.

Microcomputed tomography through the mid-diaphysis of the femur showed an
increasing trend (p=O.l) in cortical bone area (mm2 ) between the wild-type vehicles
group (n=10, 0.992±0.094) and the wild-type PTH group (n=10, 1.052±0.061). The
increase in cortical bone area (mm2 ) was significant (p=.03) between the transgenic
vehicle group (n=6, 0.803±0.091) and the transgenic PTH group (n=10,
0.935±0.130).

Figure 13: Microcomputed tomography analysis of femoral trabecular thickness.

Trabecular morphometry within the metaphyseal region of the distal femur showed a
significant increase in trabecular thickness (/-lm) between the wild-type vehicle group
(n=10, 60±6) and the wild-type PTH group (n=10, 69±9). The change in femoral
trabecular thickness (/-lm) was not significant between the transgenic vehicle group
(n=6, 55±25) and the transgenic PTH group (n=l 0, 46±20).

Figure 14: Microcomputed tomography analysis of vertebral trabecular bone
fraction. Analysis of trabecular bone volume (BVITV%) revealed a significant

increase between the transgenic vehicle group (n=6, 5.6±2.0) and the transgenic PTH
group (n=10, 7.7±2.2). The change in trabecular bone volume between the wild-type
vehicle group (n=l 0, 24.9±3.8) and the wild-type PTH group (n=10, mean 27.4±6.8)
was not significant.
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Figure 15: Analysis of bone and tooth architecture by micro computed
tomography analysis. Comparison of three dimensional microCT images of wildtype vehicle treated mandibles and transgenic vehicle treated mandibles showed an
overall view ofthe bone and tooth architecture typical ofthe lCER transgenic
phenotype: generalized pitting of the bone and severe loss of alveolar bone around the
molars. No apparent PTH effects on the bone phenotype within the wild-type or
transgenic groups were noted.

Figure 16: Microcomputed tomography analysis of cortical bone volume fraction
at the level of the 1st molar. Cross-sectional, quantitative analysis of the mandibular
cortical bone volume (BV/TV%) at the mesial root of the first molar demonstrated no
change between the wild-type vehicle group (n=7, 91.1±1.9) and the wild-type PTH
group (n=6, 91.6±1.6). There was no change between the transgenic vehicle group
(n=6, 74.7±10.2) and the transgenic PTH group (n=5, 72.0±11.6).

Figure 17: Dynamic histomorphometry analysis of wild-type vertebral mineral
apposition rate. Quantitative analysis of dynamically labeled and sectioned L3
vertebrae showed a trend (p=.07) toward increased mineral apposition rate (MAR)
between the wild-type vehicle group (n=7, 1.38±O.11) and the wild-type PTH group
(n=6, 1.54±O.18).

Figure 18: Dynamic histomorphometry analysis of wild-type vertebral bone
formation rate per bone surface. Quantitative analysis of dynamically labeled and
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sectioned L3 vertebrae showed no change in the bone formation rate per bone surface
(BFR/BS) between the wild-type vehicle group (n=7, 0.364±0.1 00) and the wild-type

PTH group (n=6, 0.415±0.100).

Figure 19: Dynamic histomorphometry analysis of transgenic vertebral bone
formation rate per bone surface. Quantitative analysis of dynamically labeled and

sectioned L3 vertebrae showed a trend (p=.06) toward increasing bone formation rate
per bone surface (BFR/BS) between the transgenic vehicle group (n=6, 0.465±0.152)
and the transgenic PTH group (n=5, O.662±0.146).

Figure 20: Dynamic histomorphometry analysis of transgenic vertebral mineral
apposition rate. Quantitative analysis of dynamically labeled and sectioned L3

vertebrae showed no change in mineral apposition rate (MAR) between the transgenic
vehicle group (n=6, 1.48±O.38) and the transgenic PTH group (n=5, 1.82±0.26).
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Figure 1
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Fig. I Osleobl:iltlic cell signaling mcdlutcll by PTH

Figure 1 from Swarthout, J.T., et aI., Parathyroid hormone-dependent signaling
pathways regulating genes in bone cells. Gene, 2002. 282(1-2): p. 3.
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Diagram kindly provided by Taranpreet Chanhoke.
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Figure 3
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Figure 9 from Molina, C.A., et aI., Inducibility and negative autoregulation of

CREM' an alternative promoter directs the expression ofICER, an early response
repressor. Cell, 1993. 75(5): p. 886.
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Figure 4
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Figure 6
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Figure 7
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Figure 9
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Figure 10
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Figure 11
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Figure 12
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Figure 13
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Figure 14
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Figure 15
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Figure 16
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Figure 17
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Figure 18
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Figure 19
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Figure 20
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